DTD1: A Key Enzyme for Protein Synthesis and Disease (G92675)

Target Name: DTD1

NCBI ID: G92675

DTD1

DTD1: A Key Enzyme for Protein Synthesis and Disease

DTD1 (D-aminoacyl-tRNA deacylase 1) is a protein that is expressed in all living cells and is involved in the process of translation of proteins from mRNA to functional proteins. It is a key enzyme in the translation machinery and is critical for the production of proteins in the cell.

DTD1 is a 25 kDa protein that is expressed in all living cells, including muscle, heart, brain, and liver cells. It is a member of the A subfamily of the translation factors, which are a group of proteins that play a critical role in the initiation of the translation of mRNAs.

The function of DTD1 is to catalyze the deacylation of tRNA on the 3'-end, which enables the tRNA to recognize and translocate the mRNA for protein synthesis. DTD1 is responsible for the last step of the process of translation, which is the release of the tRNA from the ribosome and the transfer of the amino acids to the growing chain of amino acids that is being synthesized.

DTD1 is a critical enzyme for protein synthesis, as it enables the production of a wide variety of proteins that are essential for the cell's survival and growth. Many diseases are caused by defects in protein synthesis, including genetic disorders, neurodegenerative diseases, and diseases that affect the immune system.

DTD1 is also a potential drug target, as its function in the translation machinery makes it an attractive target for small molecules that can modulate translation efficiency. The use of small molecules as drugs for the treatment of genetic disorders and neurodegenerative diseases is a rapidly growing field of research, and DTD1 is no exception.

One approach to targeting DTD1 is to use small molecules that inhibit its activity. These small molecules can be designed to interact with specific regions of DTD1, such as its active site or its substrate binding site. By inhibiting DTD1's activity, small molecules can reduce the production of proteins and improve the efficiency of the translation machinery.

Another approach to targeting DTD1 is to use small molecules that modulate its stability. DTD1 is a protein that is expressed in all living cells, and its stability is critical for its function. Small molecules that can modulate DTD1 stability and enhance its stability can be used to stabilize DTD1 and improve its stability, which can lead to increased levels of DTD1 in the cell.

In addition to its potential as a drug target, DTD1 is also a potential biomarker for a variety of diseases. Its involvement in the translation machinery makes it an attractive target for biomarkers that can be used to diagnose or predict the severity of disease. For example, DTD1 levels have been used as a biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Overall, DTD1 is a critical enzyme for the production of proteins in the cell. Its function in the translation machinery makes it an attractive target for small molecules that can modulate its activity. In addition to its potential as a drug target and biomarker, DTD1 is also a critical component of the cell's machinery for protein synthesis, making it a valuable target for research into the mechanisms of protein synthesis and disease.

Protein Name: D-aminoacyl-tRNA Deacylase 1

Functions: Possible ATPase (PubMed:15653697) involved in DNA replication, may facilitate loading of CDC45 onto pre-replication complexes (PubMed:20065034)

The "DTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets